...A. 2023 was another record-breaking year for Exact Sciences, and our fourth quarter results set the tone for an impactful year ahead. B. Highlights in 2023 include testing a record 4.1 million patients for cancer and rare diseases, growing core revenue by 24% to $2.5 billion. C. Improving adjusted EBITDA of $362 million year-over-year, turning free cash flow positive, submitting next-generation Cologuard for FDA approval. D. Launching Oncotype DX in Japan on a reimbursed basis, accelerating our molecular residual disease or MRD program, launching OncoExTra, our solid tumor therapy selection test and adding OncoLiquid, our liquid therapy selection test and advancing our multi-cancer early detection. E. Fourth quarter revenue of $647 million grew 17% or 18% on a core basis, excluding COVID testing, FX and M&A. Screening revenue of $487 million increased 21%. F. We continue to see broad-based momentum in Cologuard adoption by health care providers with an all-time high 172,000 ordering Cologuard...
